Conduritol B epoxide, Inhibitor

Conduritol B epoxide

Cat. Num. AAA5764548

• Purity: 98.00%
• Synonyms: Conduritol B epoxide; inhibitor

• Purity/Purification: 98.00%
• Form/Format: Solid. Powder

• Solubility: Water: 20mg/mL (123.35mM); (<1mg/ml refers to the product slightly soluble or insoluble)
• Formula: C6H8O5
• SMILES: O[C@@H]1[C@@H](O)[C@](O)[C@@H](O)[C@]2[C@@H]1O2
• CAS Number: 6090-95-5
• Kinase Assay: Cells are homogenized in 1% sodium taurocholate/1% Triton X-100. GCase activity is determined fluorometrically using 4MU-Glucose as the substrate in 0.25% sodium taurocholate, 0.25% Triton X-100 and 0.1M citric-phosphate buffer (pH 5.6). Brain tissues are homogenized in 1X PBS and incubated in 5uM brain phosphatidylserine and 0.1M citric-phosphate buffer (pH 5.6) for GCase activity assay using 4MU-Glucose as substrate. Protein concentrations are determined by BCA assay using BSA as standard [1].
• In Vitro: Treating N2a and Conduritol B epoxide-N2a cells with G6 gave GC reductions to 7% and 26% of untreated levels, respectively. G6 treated Conduritol B epoxide-N2a also has significantly decreased GS. Conduritol B epoxide-N2a cells have higher calcium levels than in N2a cells without caffeine at baseline. Conduritol B epoxide-N2a cells show a significant increase in cytosolic calcium levels compared to N2a cells. Conduritol B epoxide-N2a cells show a significant reduction in OCR as evidenced by approximately 50% in all the parameters, including the rate of ATP production, basal respiration, and maximal respiration, compared to N2a cells. In dantrolene-treated Conduritol B epoxide-N2a cells, levels of Ryr3 are increased to 76% of the WT level [1].
• Preparation and Storage: Store at -20 degree C for 3 years powder; -80 degree C for 2 years in solvent

Related Product Information for Conduritol B epoxide, inhibitor

Conduritol B epoxide is an irreversible inhibitor of beta-glucosidase (GCase).

Product Categories/Family for Conduritol B epoxide, inhibitor

Metabolism; Glucokinase

References

Liou B, et al. Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice. Hum Mol Genet. 2016 Sep 20. pii: ddw322. [Epub ahead of print]
Liou B, et al. Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice. Hum Mol Genet. 2016 Sep 20. pii: ddw322. [Epub ahead of print]
YH Xu, et al. Accumulation and distribution of alpha-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab. Author manuscript; available in PMC 2012 Apr 1
YH Xu, et al. Accumulation and distribution of alpha-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab. Author manuscript; available in PMC 2012 Apr 1